Report an error
Spotted something inaccurate in “Envafolimab's Subcutaneous Delivery May Expand PD-L1 Blockade Access”? Tell us what’s wrong and we’ll check it against the original source.
This form is for factual corrections. We read every report but cannot reply individually.